On May 17, 2023 Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, reported that it will present new data for CPI-818, the Company’s ITK inhibitor, at the International Conference on Malignant Lymphoma (ICML) meeting, which is taking place June 13-17, 2023 in Lugano, Switzerland (Press release, Corvus Pharmaceuticals, MAY 17, 2023, View Source [SID1234631804]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We continue to make strong progress in the development of ITK inhibition as a potential platform opportunity with a novel mechanism of action that can address a broad range of hematologic and solid cancers and immune diseases," said Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus. "We look forward to presenting data at ICML supporting the biology and mechanism of immune enhancement resulting from selective ITK inhibition, along with the latest clinical data from our Phase 1/1b clinical trial of CPI-818 for T cell lymphoma. CPI-818 is the main priority for Corvus and we remain on track for initiating a potential registrational Phase 3 randomized trial for T cell lymphoma later this year."
Details regarding the CPI-818 poster presentation at ICML, which will be available on the Corvus website, are as follows:
Date and Time: Thursday, June 15, 2023, from 12:30 to 1:00 pm CEST (6:30 – 7:00 am ET)
Title: ITK inhibitor induces Th1 skewing and host anti-tumor response mediated by CD8+ TEMRA cells in refractory T cell lymphoma patients
Abstract #: 193
Presenter: Ning Ding, Ph.D., Peking University Cancer Hospital & Institute, Beijing, China
The poster will be available to attendees in the poster hall on Wednesday, June 14 from 12:00 – 6:00 pm CEST and Thursday-Friday, June 15-16 from 10:00 am – 6:00 pm CEST. It will also be accessible to attendees beginning on Wednesday, June 14 at 8:30 am CEST in the e-poster gallery.
CPI-818 is currently being studied in a Phase 1/1b clinical trial as a single agent therapy in patients with relapsed TCL. Corvus recently incorporated a minimum absolute lymphocyte count (ACL) as an eligibility criterion for enrollment in the clinical trial. Based on the current enrollment rate of the Phase 1/1b clinical trial, Corvus believes that the number of patients treated in this clinical trial would provide adequate safety and preliminary efficacy data to inform the design of a potential registrational Phase 3 randomized clinical trial. As recommended by the FDA, Corvus plans to meet with the FDA to discuss such a clinical trial; it is anticipated that this meeting will take place during the third quarter of this year.